Enlivex Therapeutics Ltd Quick Ratio (ENLV) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Enlivex Therapeutics Ltd  (NASDAQ: ENLV)

Enlivex Therapeutics Ltd's Quick Ratio

ENLV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.6 below Enlivex Therapeutics Ltd's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 356 other companies have achieved higher Quick Ratio than Enlivex Therapeutics Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 2103.

Explain Quick Ratio?
How much Cash & cash equivalents ENLV´s has?
What are ENLV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENLV Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q2
Y / Y Current Liabilities Change 146.68 % 216.3 % -38.74 % 86.85 % -87.6 %
Y / Y Cash & cash equivalent Change -75.98 % -78.01 % -39.83 % -82.25 % -37.19 %
Quick Ratio MRQ 0.6 0.64 5.86 0.64 6.19
ENLV's Total Ranking # 2103 # # # #
Seq. Current Liabilities Change 0 % 171.06 % -63.11 % 146.68 % 28.23 %
Seq. Cash & cash equivalent Change -5.46 % -70.51 % 239.06 % -74.59 % -13.45 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 357
Healthcare Sector # 666
Overall Market # 2103


Quick Ratio Statistics
High Average Low
18.27 8.73 0.64
(Dec 31 2021)   (Dec 31 2025)




Financial Statements
Enlivex Therapeutics Ltd's Current Liabilities $ 9 Millions Visit ENLV's Balance sheet
Enlivex Therapeutics Ltd's Cash & cash equivalent $ 5 Millions Visit ENLV's Balance sheet
Source of ENLV's Sales Visit ENLV's Sales by Geography


Cumulative Enlivex Therapeutics Ltd's Quick Ratio

ENLV's Quick Ratio for the trailling 12 Months

ENLV Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 81.22 % -41.26 % -57.7 % -56.33 % -66.31 %
Y / Y Cash & cash equivalent TTM Growth -67.92 % -57.77 % -44.44 % -16.06 % -6.41 %
Quick Ratio TTM 1.2 2.14 3.93 4.15 6.78
Total Ranking TTM # 2846 # # # #
Seq. Current Liabilities TTM Growth 21.43 % 32.71 % -10.04 % 25 % -60.64 %
Seq. Cash & cash equivalent TTM Growth -32.06 % -27.56 % -14.84 % -23.46 % -10.55 %

Quick ratio ranking by company, industry and sector >> Back to ENLV Financial Strength Comparisons >> Go to Compare ENLV Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $9.02 millions, cumulative Quick Ratio decreased to 1.2 below the Enlivex Therapeutics Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 375 other companies have achieved higher Quick Ratio than Enlivex Therapeutics Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 2846.

Explain Quick Ratio?
How much Cash & cash equivalents ENLV´s has?
What are ENLV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 376
Healthcare Sector # 774
Within the Market # 2846


trailing twelve months Quick Ratio Statistics
High Average Low
17.83 8.04 2.01
(Dec 31 2021)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Zai Lab Limited  1.62 $ 688.358  Millions$ 424.417  Millions
Alaunos Therapeutics Inc   1.60 $ 1.385  Millions$ 0.867  Millions
Fortress Biotech Inc   1.60 $ 79.381  Millions$ 49.744  Millions
Geovax Labs Inc   1.59 $ 3.086  Millions$ 1.937  Millions
Elite Pharmaceuticals Inc   1.58 $ 21.095  Millions$ 13.358  Millions
Werewolf Therapeutics Inc   1.58 $ 57.050  Millions$ 36.148  Millions
Therapeuticsmd Inc   1.56 $ 7.483  Millions$ 4.785  Millions
Rigel Pharmaceuticals Inc  1.56 $ 154.955  Millions$ 99.237  Millions
Emergent Biosolutions Inc   1.55 $ 205.400  Millions$ 132.200  Millions
Integrated Biopharma Inc  1.50 $ 5.314  Millions$ 3.541  Millions
60 Degrees Pharmaceuticals Inc   1.49 $ 2.751  Millions$ 1.843  Millions
Maia Biotechnology Inc   1.48 $ 8.658  Millions$ 5.836  Millions
Apellis Pharmaceuticals Inc   1.47 $ 466.233  Millions$ 316.509  Millions
Alzamend Neuro Inc   1.46 $ 2.713  Millions$ 1.857  Millions
Sarepta Therapeutics Inc   1.43 $ 939.650  Millions$ 656.648  Millions
Legend Biotech Corporation  1.42 $ 901.900  Millions$ 636.400  Millions
Indaptus Therapeutics Inc   1.38 $ 8.508  Millions$ 6.159  Millions
Macrogenics Inc   1.38 $ 57.217  Millions$ 41.586  Millions
Arcutis Biotherapeutics Inc   1.37 $ 178.075  Millions$ 129.838  Millions
Addex Therapeutics Ltd  1.37 $ 1.639  Millions$ 1.199  Millions
Inovio Pharmaceuticals Inc   1.34 $ 58.512  Millions$ 43.669  Millions
Inventiva S a   1.31 $ 113.784  Millions$ 86.663  Millions
Theriva Biologics inc   1.30 $ 13.056  Millions$ 10.014  Millions
Moleculin Biotech Inc   1.30 $ 8.878  Millions$ 6.854  Millions
Uniqure N v   1.28 $ 80.240  Millions$ 62.919  Millions
Apimeds Pharmaceuticals US, Inc.  1.26 $ 13.273  Millions$ 10.545  Millions
Vireo Growth Inc.  1.25 $ 103.230  Millions$ 82.545  Millions
Vanda Pharmaceuticals Inc   1.24 $ 84.851  Millions$ 68.297  Millions
Amicus Therapeutics inc   1.23 $ 293.536  Millions$ 237.828  Millions
Nkarta Inc   1.23 $ 39.634  Millions$ 32.122  Millions

Date modified: 2026-10-27T15:09:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.